News | Oncology Diagnostics | May 01, 2018

Pilot Study Initiated for Blood-Based Breast Test

Liquid biopsy increases clarity of inconclusive screening mammogram results, may reduce incidence of invasive biopsies

Pilot Study Initiated for Blood-Based Breast Test

May 1, 2018 — Overlake Medical Center in Bellevue, Wash., announced it has enrolled 85 patients in a pilot study of a blood test to assess breast cancer risk. The test may determine which women with abnormal or inconclusive screening mammography results are at low risk for invasive breast cancer. This technology, requiring a simple blood draw, will help physicians assess the likelihood of invasive cancer or precancerous lesions with difficult-to-interpret mammogram images, thus potentially reducing the need for invasive biopsies.

The EarlyGuard Breast Test is being developed by Toray Molecular Oncology Laboratory (TMOL) in Brisbane, Calif. The multi-center prospective clinical trial is enrolling 400 patients at seven medical institutions nationwide. Overlake is the only hospital in Washington State participating, and is the second highest enrolling site nationwide.

Despite its effectiveness in reducing breast cancer deaths, screening mammography is associated with a high false positive rate, or inconclusive results that lead to costly and invasive follow-up procedures, such as additional breast imaging tests or a tissue biopsy. “It’s satisfying to be a part of advancing science,” said Overlake’s Steve Scallon, M.D., the study’s principal investigator. “It may be a helpful way for clinicians to better differentiate between high- and low-risk patients in the future.”

According to the American Cancer Society, for every woman screened, approximately 10 percent will be recalled for further testing, of which only three percent ultimately will be diagnosed with breast cancer. According to the Centers for Disease Control and Prevention, over 65 percent of women in the U.S. over the age of 40 are being screened every other year. For those patients who have been recommended to have an ultrasound guided biopsy, 75 percent of them will have a negative result. These false positives have the consequence of increased short-term anxiety for the women undergoing evaluation.

For patients like Reshil Offutt of Woodinville, Wash., whose screening mammography placed her in the American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS) Category 4 meaning suspicious for malignancy, the waiting period before the biopsy and afterwards while waiting for results was stressful. “I scaled back on work after the biopsy and spent that week researching online and worrying,” said Offutt, whose biopsy showed her lump to be benign. “Anything that shortens the wait time is a good thing.”

Results of the pilot study are expected in early summer 2018. A pilot study is a necessary first step in exploring a new clinical intervention. A larger efficacy trial is expected to start in winter 2018.

For more information: www.toray.com

 

Related Content

Joseph J. Cappello Named Executive Director of Are You Dense Nonprofits
News | Breast Density | February 20, 2019
The boards of Are You Dense Inc. and Are You Dense Advocacy Inc., founded by the late Nancy M. Cappello, Ph.D.,...
Congress Directs FDA to Establish Federal Breast Density Inform Standard
News | Breast Density | February 19, 2019 | Jeff Zagoudis, Associate Editor
As part of a federal spending bill passed late Friday, Congress directed the U.S. Food and Drug Administration (FDA) to...
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Densitas Enters Partnership Agreement With TeleMammography Specialists
News | Breast Density | February 14, 2019
Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography...
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
Mount Sinai's Digital 3-D Mammography Van Rolls Into New York City
News | Mammography | February 11, 2019
Mount Sinai Hospital recently launched the Mount Sinai Mobile Mammography Program (MMP), bringing essential breast...
breast density cancer awareness
News | Breast Density | February 08, 2019
Governor Michelle Lujan Grisham has signed breast density inform bill, ...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...